https://www.selleckchem.com/pr....oducts/pirtobrutinib
Similar data were obtained during the second follow-up visit. The analysis of a subgroup of patients with at least 2 follow-up visits and known LDL-C levels showed that the percentage of patients at goal increased from 9% to 32%, and patients with LDL-C 100mg/dL raised from 23% to 72%. Among acute cases, 44 were admitted with a diagnosis of familial hypercholesterolemia (FH); only 18% of the remaining patients were screened for FH. Contemporary lipid management of very high CV risk patients is sub-optimal despite avai
Curtir
Comentario
Compartilhar
